{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:51:43Z","timestamp":1782125503805,"version":"3.54.5"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Bladder cancer (BC) is the second most common genitourinary malignancy, with substantial racial disparities in survival. This study assessed racial and ethnic differences across key stages of BC care among US Medicare beneficiaries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study analyzed Medicare fee-for-service claims (2021\u20132022) and included patients with newly diagnosed BC (ICD-10-CM code C67). Differences in diagnosis, specialty care access, and treatment across racial and ethnic groups (White, Black or African American, Hispanic, Asian or Pacific Islander, American Indian or Alaska Native, Other, or Unknown) were evaluated using rate ratios (RRs), with White patients as the reference group. Median times from diagnosis to first specialist referral and to treatment initiation were also assessed. Outcomes are reported using descriptive statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 136, 172 patients met the study criteria: 116, 043 (85.2%) White, 7, 768 (5.7%) Black or African American, 5, 733 (4.2%) Hispanic, 2, 729 (2.0%) Asian or Pacific Islander, 365 (&amp;lt;1%) American Indian or Alaska Native, and 3, 534 (2.6%) patients of Other or Unknown race. The RRs for BC diagnosis and receipt of any treatment were below 1.0 across all racial and ethnic groups. Compared with White patients, Hispanic and Black or African American patients had less access to specialists (Hispanic: RR\u00a0=\u00a00.891; 95% confidence interval [CI], 0.865\u20130.918; Black or African American: RR\u00a0=\u00a00.930; 95% CI, 0.906\u20130.954), had lower rates of receiving any treatment (Hispanic: RR\u00a0=\u00a00.806; 95% CI, 0.765\u20130.850; Black or African American: RR\u00a0=\u00a00.814; 95% CI, 0.775\u20130.856), and experienced longer median times from diagnosis to treatment initiation (31 days for both groups vs 25 days for White patients). Hispanic and American Indian or Alaska Native patients also had longer median times from initial diagnosis to first specialist visit (26 and 28 days, respectively) compared with White patients (23 days).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Racial disparities in BC care across the care continuum were observed. These findings can inform conversations with population health decision makers and policy-level stakeholders to identify solutions to help improve care for minoritized racial and ethnic groups. Further research is needed to understand the underlying drivers and develop evidence-based strategies to ensure equitable access to care for all patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1797699","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:18:46Z","timestamp":1782123526000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Racial and ethnic differences in bladder cancer diagnosis, treatment, and specialty care access among Medicare fee-for-service beneficiaries: a cross-sectional study"],"prefix":"10.3389","volume":"16","author":[{"given":"Atreyee","family":"Majumder","sequence":"first","affiliation":[{"name":"Johnson & Johnson","place":["Titusville, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Dwyer Orr","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Titusville, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","unstructured":"Cancer stat facts: Bladder cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2025","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(09)60080-x","article-title":"Ethnic differences in bladder cancer survival","volume":"78","author":"Yee","year":"2011","journal-title":"Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102728","article-title":"Racial differences in carcinoma-in-situ and non-muscle-invasive bladder cancer mortality: Accounting for insurance status, black segregation, and neighborhood poverty","volume":"94","author":"Johnson","year":"2025","journal-title":"Cancer Epidemiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.02.008","article-title":"Disparities in patient and system factors explain racial\/ethnic disparities in delayed time to treatment in muscle invasive bladder cancer","volume":"40","author":"Buac","year":"2022","journal-title":"Urol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e995","DOI":"10.1016\/j.clgc.2019.05.008","article-title":"Racial and socioeconomic disparities in bladder cancer survival: Analysis of the california cancer registry","volume":"17","author":"Sung","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.01.013","article-title":"Characteristics contributing to survival differences between black and white patients\u00a0following cystectomy","volume":"41","author":"Rosenzweig","year":"2023","journal-title":"Urol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab219","article-title":"Association of health-care system and survival in african american and non-hispanic white patients with bladder cancer","volume":"114","author":"Kotha","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31926","article-title":"Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival","volume":"125","author":"Cole","year":"2019","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.06.087","article-title":"Sex and racial disparities in the treatment and outcomes of muscle-invasive bladder cancer","volume":"151","author":"Marinaro","year":"2021","journal-title":"Urology"},{"key":"B11","volume-title":"Understanding and mitigating disparities in baldder cancer care","year":"2022"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/23523735241289237","article-title":"Achieving health equity in bladder cancer care: Addressing disparities through collaborative research and evidence-based strategies","volume":"10","author":"Castellon-Lopez","year":"2024","journal-title":"Bladder Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0001109788.99555.df.16","article-title":"Mp08-16 disparities and temporal trends in referral for bladder cancer diagnosis: A worsening epidemic","volume":"213","author":"Myers","year":"2025","journal-title":"J Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3747\/co.22.2052","article-title":"Urologist referral delay and its impact on survival after radical cystectomy for bladder cancer","volume":"22","author":"Santos","year":"2015","journal-title":"Curr Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.21037\/tau-24-148","article-title":"Association between time to treatment and bladder cancer survival: A population-based analysis","volume":"13","author":"Hou","year":"2024","journal-title":"Transl Androl Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1001843","article-title":"Impact of the time of surgical delay on survival in patients with muscle-invasive bladder cancer","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4087","article-title":"Mortality due to cancer treatment delay: Systematic review and meta-analysis","volume":"371","author":"Hanna","year":"2020","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-025-01072-0","article-title":"Low-grade non-muscle-invasive bladder cancer: Molecular landscape, treatment strategies and emerging therapies","volume":"22","author":"Wen","year":"2025","journal-title":"Nat Rev Urol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.3390\/cancers17132070","article-title":"Novel strategies and therapeutic advances for bladder cancer","volume":"17","author":"Ehrlich","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.12.264","article-title":"Development of tar-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer","volume":"43","author":"Daneshmand","year":"2025","journal-title":"Urol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1519428","article-title":"Updated review on novel therapies and ongoing clinical trials for high-risk non-muscle invasive bladder cancer","volume":"15","author":"Wiesen","year":"2025","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000004452","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: Aua\/suo guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3233\/blc-230074","article-title":"A procedural checklist for transurethral resection of bladder tumors (turbt) enhances operative dictation and assesses surgeon accuracy of tumor characteristic predictions","volume":"9","author":"Dave","year":"2023","journal-title":"Bladder Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2019.09.38","article-title":"Transurethral resection of bladder tumour (turbt)","volume":"9","author":"Kim","year":"2020","journal-title":"Transl Androl Urol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4917","article-title":"Racial inequity and other social disparities in the diagnosis and management of bladder cancer","volume":"12","author":"Hasan","year":"2023","journal-title":"Cancer Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16380","article-title":"Racial disparities in stage at bladder cancer diagnosis in the us veterans affairs healthcare system","volume":"134","author":"Bree","year":"2024","journal-title":"BJU Int"},{"key":"B27","doi-asserted-by":"publisher","first-page":"237 e9","DOI":"10.1016\/j.urolonc.2017.12.015","article-title":"Discrepancies in staging, treatment, and delays to treatment may explain disparities in bladder cancer outcomes: An update from the national cancer data base (2004-2013)","volume":"36","author":"Weiner","year":"2018","journal-title":"Urol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3429","article-title":"Race modifies survival benefit of guideline-based treatment: Implications for reducing disparities in muscle invasive bladder cancer","volume":"9","author":"Washington","year":"2020","journal-title":"Cancer Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/op.2024.20.10_suppl.150","article-title":"Health care disparities and bladder cancer mortality in the United States: A closer look at the social vulnerability index","volume":"20","author":"Haniff","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-021-01414-4","article-title":"Patterns of overall mortality by race\/ethnicity and socioeconomic status in insured cancer patients in southern california","volume":"32","author":"Cooper","year":"2021","journal-title":"Cancer Causes Control"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2018.03.008","article-title":"Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer","volume":"36","author":"Klapheke","year":"2018","journal-title":"Urol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaf054","article-title":"Socioeconomic disparities and bladder cancer stage at diagnosis: A statewide cohort analysis","volume":"9","author":"Finocchiaro","year":"2025","journal-title":"JNCI Cancer Spectr"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5382","article-title":"Association of residential racial and economic segregation with cancer mortality in the us","volume":"9","author":"Zhang","year":"2023","journal-title":"JAMA Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/bju.70151","article-title":"Area deprivation and cancer-specific mortality in non-muscle-invasive bladder cancer: A statewide analysis","volume":"137","author":"Silvani","year":"2026","journal-title":"BJU Int"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1797699\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:18:56Z","timestamp":1782123536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1797699\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":34,"alternative-id":["10.3389\/fonc.2026.1797699"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1797699","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1797699"}}